[The expressions and clinical significance of IGFBP-2, -3 in both serum and tumor tissues in patients with epithelial ovarian cancer].
Sichuan Da Xue Xue Bao Yi Xue Ban
; 40(4): 639-43, 2009 Jul.
Article
em Zh
| MEDLINE
| ID: mdl-19764562
ABSTRACT
OBJECTIVE:
To explore the serum levels of IGFBP-2, -3 and their proper roles in the regulation of IGF-II bioavailability in patients with ovarian tumor, and to investigate the correlation between the expressions of IGFBP-2 and IGFBP-3 in ovarian tumor tissues and related clinicopathological characteristics.METHODS:
Serum levels of IGFBP-2, -3 and big/mature IGF-II were measured by Western ligand blot (WLB) and Western blot (WB) in patients with ovarian tumor (10 cases of benign tumor, 6 cases of borderline tumor and 10 cases of malignant tumor) and 10 cases of normal control. The expressions of IGFBP-2 and IGFBP-3 were examined in 39 specimens of ovarian tumor (8 cases of benign tumor, 8 cases of borderline tumor and 23 cases of malignant tumor) and 4 cases of normal ovarian tissues by immunohistochemical staining.RESULTS:
The serum levels of both big and mature IGF-II in epithelial ovarian cancer (ovarian cancer) patients were significantly decreased compared with those of normal control and benign and borderline tumor (P<0.001 or P<0.01). The increased serum level of IGFBP-2 and decreased IGFBP-3 level were observed in patients with malignant ovarian tumors by comparing with those of patients with normal controls, benign and borderline tumor (P<0.001 or P<0.01). The expression of IGFBP-2 was significantly higher in malignant ovarian tumor tissues than those in normal control and benign ovarian tumors tissues (P<0.0001, P<0.001, and the expression of IGFBP-3 decreased significantly in lower differentiated ovarian cancer tissues compared with that in high and moderate differentiated ovarian cancer tissues (P<0. 05). CONCLUION IGFBP-2 predominantly presents in the circulation of malignant patients in contrast to IGFBP-3, which may result in altered bioavailability of IGF-II in ovarian cancer, leading to the progress of tumor. The serum levels of both IGFBP-2 and IGFBP-3 and their expressions in tumor tissues are correlated with the clinicopathological characteristics of ovarian cancer patients. Our findings suggest that the presence of new mechanisms in the regulation of IGF-II bioavailability, and provide the evidence for the possibility to use IGFBP-2/IGFBP-3 as biological markers in diagnosis and prognosis of ovarian cancer.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Fator de Crescimento Insulin-Like II
/
Proteína 2 de Ligação a Fator de Crescimento Semelhante à Insulina
/
Proteína 3 de Ligação a Fator de Crescimento Semelhante à Insulina
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
Zh
Revista:
Sichuan Da Xue Xue Bao Yi Xue Ban
Ano de publicação:
2009
Tipo de documento:
Article
País de afiliação:
China